Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Andexanet alfa effectively reverses factor Xa inhibition

Key clinical point: Andexanet alfa significantly reduces anti–factor Xa activity.

Major finding: Approximately 82% of treated patients achieved good or excellent hemostasis.

Study details: A single-cohort study of 352 patients with acute major bleeding associated with factor Xa inhibition.

Disclosures: Portola Pharmaceuticals, the maker of andexanet alfa, funded the study.

Citation:

Milling TJ et al. ISC 2019, Abstract LB7.